ArticleJournal of diabetes and metabolic disorders2026
Body mass index mediates the association between serum fibroblast growth factor-19 and diabetes.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to investigate the relationship between serum fibroblast growth factor-19 (FGF19) levels and diabetes, as well as the potential mediating role of body mass index (BMI). Methods: Data from 1,018 participants with valid serum FGF19 measurements from the Shenzhen-Hong Kong United Network on Cardiovascular Disease study were analyzed. Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for diabetes risk. Mediation analysis was conducted to assess the extent to which BMI mediated the association between serum FGF19 levels and diabetes. Results: The mean age of participants was 45.1 years, with 77 individuals (7.6%) diagnosed with diabetes. Natural logarithm (ln)-transformed FGF19 levels were inversely associated with BMI [age- and sex-adjusted β (95% CI): -0.30 (-0.58, -0.03)]. Ln-transformed FGF19 levels were also negatively associated with diabetes after adjusting for covariates, including age, sex, smoking status, alcohol consumption, blood pressure, BMI, waist circumference, and lipid profile [OR (95% CI): 0.66 (0.47-0.95)]. No significant interactions were observed between ln-transformed FGF19 levels and age, sex, obesity, or abdominal obesity in relation to diabetes. Mediation analysis revealed that BMI reduction accounted for 10.1% of the association between ln-transformed FGF19 levels and diabetes. Conclusion: Serum FGF19 levels are inversely associated with diabetes risk in the Chinese population, with BMI serving as a partial mediator of this relationship. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01850-y.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.